Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Ca...(aiwan and principal investigator ofthe t...),Health

Additional results from the trial are as follows:

-- Median time to progression was 2.8 months in Nexavar-treated patients

versus 1.4 months for those taking placebo.

-- Median time to symptomatic progression was 3.5 months in patients

treated with Nexavar versus 3.4 months for those taking placebo.

-- Disease control rate (complete response + partial response + stable

disease >/= 12 weeks) was 35 percent in Nexavar-treated patients versus

16 percent for those taking placebo.

Data from the study indicate that Nexavar was safe and well-tolerated in patients from the Asia-Pacific region. Adverse events were low to moderate in severity and treatment was well tolerated. The most common serious adverse events observed in the study were hand-foot-skin reaction, diarrhea, alopecia, fatigue, and rash/desquamation.

"These data provide further evidence that Nexavar is efficacious in liver cancer across multiple geographical regions and independent of disease characteristics and etiologies of underlying liver disease," said Susan Kelley, MD, Vice President, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. "Nexavar has quickly become the systemic standard of care for liver cancer, and is the only systemic therapy that has been shown to improve overall survival in Asian patients with liver cancer."

Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. More than 600,000 cases of liver cancer are
'/>"/>